Pharco Pharmaceuticals has inaugurated a specialized production line for eye drops at its Amreya City facility in Alexandria, with investments exceeding EGP 500m. The line has an annual capacity of 20 million packs, covering about 19% of Egypt's domestic demand. It supports efforts to localize drug manufacturing and reduce import reliance.
Pharco Pharmaceuticals inaugurated a new ophthalmic eye drops production line at its Amreya City facility in Alexandria, with nearly EGP 300m allocated to the line from total investments over EGP 500m. The facility produces treatments for dry eye, glaucoma, inflammation, post-surgical care, and allergies.
The line has an annual capacity of up to 20 million packs, meeting around 19% of Egypt's domestic demand exceeding 100 million packs yearly, and 11% of demand across Egypt, the Middle East, and Africa over 177 million packs. Sherine Helmy, Chairperson of Pharco, stated: “This expansion reinforces Pharco’s commitment to localizing advanced pharmaceutical manufacturing and enhancing Egypt’s global competitiveness. With annual sales surpassing 278 million units valued at nearly EGP 15bn, Pharco continues to play a leading role in advancing Egypt’s pharmaceutical industry.”
The facility complies with Egyptian Drug Authority and World Health Organization standards, operating under Good Manufacturing Practice with aseptic processing and gamma sterilization in collaboration with the Egyptian Atomic Energy Authority. The launch was attended by Ali El Ghamrawy, Chairperson of the Egyptian Drug Authority; Hesham Badr, Vice Chairperson of the Unified Procurement Authority; Khaled Faied, CEO of Pharco; and Amr Saleh, General Manager of Pharco Oncology and Ophthalmology, along with ophthalmology professors and media representatives.
Pharco has also expanded penicillin tablet and semi-solid product lines, alongside a digital transformation initiative and new R&D center, supporting WHO and EU-GMP certifications.